• Quick Order
  • Careers
  • Support
CRISPR-Cas9 system iStock-859573154.jpg

Integrating ATCC Authenticated Cell Lines into your CRISPR Gene Editing Workflows Webinar

April 18, 2024, at 12:00 PM ET


CRISPR genome-editing platforms are being increasingly employed to accelerate drug discovery and cell and gene therapy applications. However, the cells that are critical feedstocks for these applications are complex, and not all cells are equal. To empower scientists to cogently incorporate genome editing into their workflows, ATCC has partnered with the genome editing company EditCo. In this collaboration, ATCC will offer its extensive collection of mammalian and mouse cell lines for genome engineering. Here, ATCC experts will discuss points to consider when choosing cells for editing, including cell procurement, banking, authentication, and characterization at ATCC. Next, an EditCo scientist will showcase the applications of the many genome editing workflows that they provide. Finally, the webinar will close with a lively Q and A session where industry leaders will discuss the audience’s questions.

Key takeaways:

  • Cell authentication and quality control are critical when choosing cells for CRISPR gene editing
  • ATCC is expanding its characterization program to include bioinformatic data associated with cell lines
  • EditCo provides made-to-order edited cells with industry leading turnaround time
  • EditCo’s engineered cells broaden the accessibility of CRISPR as a discovery tool


Daniel Orozco.jpg

Daniel Orozco, MS

Senior Research Associate, Scientific Development, EditCo Bio

Daniel Orozco is a Senior Research Associate at EditCo Bio under the Scientific Development Team. Mr. Orozco has 4 years of experience developing high throughput CRISPR-Cas9 gene editing platforms. His work now mainly focuses on developing and expanding EditCo’s product offerings by incorporating primary cells into the organization's gene editing platforms. Daniel has a MS in Molecular Biology from San Jose State University.

Headshot of Fang Tian, PhD

Fang Tian, PhD

Director, Biological Content, ATCC

Dr. Fang Tian, Director of Biological Content for ATCC, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.

Utsav Sharma, Headshot

Utsav Sharma, PhD

Product Manager, Oncology, ATCC

Dr. Utsav Sharma is the Product Manager for the Oncology portfolio at ATCC. Utsav obtained his PhD in Cancer Biology at the University of Miami School of Medicine, and completed his postdoctoral training at Georgetown University, focused on the tumor microenvironment, metastasis, liquid biopsy, and clinical cancer research. Prior to ATCC, Utsav worked as a Senior Scientist at Autolus Therapeutics PLC on their CD19 CAR-T platform Obe-cel, providing technical and scientific oversight to the global phase-II clinical trial on adults with Acute Lymphoblastic Leukemia (ALL) disease. Utsav has a passion for cell-based research and aims to use his scientific and business development background to partner with clients to accelerate their work using the next generation services and product offerings from ATCC.